The question anyone would ask first
Imagine you are told about a new treatment tested in diabetic mice. What is the first thing you want to know?
Did it lower their blood sugar?
That is the question this paper does not answer.
What is there, and what is not
The study measured blood sugar carefully, using glucose tolerance tests at 8 and 24 weeks of age. That was to confirm which mice were diabetic before treatment started.
Then the mice were treated for four weeks with SS-31 or saline. At the end, the team measured hydrogen peroxide, membrane damage, ATP, genes and proteins in the liver, and looked at liver slices under a microscope.
What the paper does not report is blood sugar, glucose tolerance or body weight in the SS-31 treated mice after treatment. The before-treatment numbers are there. The after-treatment comparison is missing.
Why that matters so much
This is not a nitpick. It goes to the heart of how you read every other result.
There are two very different ways SS-31 could have improved the liver's mitochondria:
Option one: SS-31 protected the mitochondria directly, while blood sugar stayed just as high. That would mean the peptide shields cells from the damage of high sugar. That is a striking claim.
Option two: SS-31 lowered blood sugar or reduced weight, and the mitochondria recovered because they were under less sugar stress. That would still be interesting, but it is a different story entirely.
The title of the paper says SS-31 protects against "hyperglycemia-induced" mitochondrial problems. To support that framing, you would want to know whether hyperglycaemia was still present in the treated mice. The paper does not tell us.
Other points worth knowing
The missing glucose data is the biggest issue. It is not the only one.
Small groups. Six mice per group, as stated in the figure legends. That is common for this kind of work, but it limits how confident you can be, especially with p-values sitting right at 0.04 for several gene results.
Different strain for controls. The healthy controls are SWR/J mice, which share 86.8% of their genetic identity with TH mice. That is close, but differences between the control and diabetic groups could partly come from the 13% of the genome that differs, not only from diabetes. This affects the "diabetic versus healthy" comparisons. It does not affect the "SS-31 versus untreated diabetic" comparison, which uses the same strain.
Antibody list. The paper's table of antibodies used for protein measurements lists Drp1, Mfn1, Fis1, Mfn2 and a reference protein. It does not list antibodies for Opa1, PGC-1α, Nrf1, Nrf2 or TFAM, yet protein results are reported for all of them. That may be an omission in the table rather than in the experiment, but it is the kind of detail that would normally be included.
A labelling slip. In the discussion, the paper describes the biogenesis proteins (PGC-1α, Nrf1, Nrf2, TFAM) under the heading of "fusion". Those are two different systems, as Parts 4 and 5 explained. It looks like a writing error, not a scientific one, but it is the sort of thing careful review usually catches.
Fold changes without direction. The results table lists fold changes for Drp1 and Fis1 as 1.6 without marking them as decreases, even though the text says they went down. Again, small, but it can mislead a reader who only looks at the table.
The Alzheimer's framing
The paper is introduced as part of a larger effort to understand the link between type 2 diabetes and Alzheimer's disease. That is a worthwhile goal and the group has a long record in that area.
But this study measures the liver. It does not include any brain measurements or memory tests. The brains were collected, according to the methods, but no results from them appear in this paper. So any link to Alzheimer's here is a hypothesis carried in from earlier work, not something this study tested.
So what is the honest summary?
This paper shows that in male diabetic TallyHo mice, four weeks of SS-31 was followed by healthier-looking liver mitochondria on a range of measures: less hydrogen peroxide, less membrane damage, more ATP, a better balance of splitting and merging, more signals for building new mitochondria, and healthier-looking liver cells.
That is a consistent set of findings and a good reason to keep studying SS-31 in diabetes.
What it does not show is whether SS-31 did any of this while blood sugar stayed high, whether it changed the diabetes itself, or whether any of it reaches the brain. Until those questions are answered, the most accurate description is: SS-31 was associated with better liver mitochondria in diabetic mice, for reasons that are not yet clear.
If you ever see this paper quoted as evidence that SS-31 "treats diabetes" or "protects against Alzheimer's", you now know exactly which number to ask for.
This series discusses a peer-reviewed laboratory study in mice. The results have not been shown in people. Nothing here is medical advice, and SS-31 is discussed for research purposes only.
